{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:22:12Z","timestamp":1762600932132,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014554","name":"Janssen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clml.2025.05.006","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T20:59:13Z","timestamp":1746737953000},"page":"e604-e611.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes for Multiple Myeloma Patients With Prior Exposure to a Combination of a Proteasome Inhibitor and an Immunomodulatory Agent in Alberta, Canada"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9294-9437","authenticated-orcid":false,"given":"Victor H.","family":"Jimenez-Zepeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariet Mathew","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winson Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clml.2025.05.006_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.clml.2025.05.006_bib0002","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"18","key":"10.1016\/j.clml.2025.05.006_bib0003","doi-asserted-by":"crossref","first-page":"E615","DOI":"10.1503\/cmaj.240095","article-title":"Projected estimates of cancer in Canada in 2024","volume":"196","author":"Brenner","year":"2024","journal-title":"CMAJ"},{"year":"2023","series-title":"Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2023","key":"10.1016\/j.clml.2025.05.006_bib0004"},{"issue":"6","key":"10.1016\/j.clml.2025.05.006_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063112","article-title":"Pathogenesis and treatment of myeloma-related bone disease","volume":"23","author":"Gau","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clml.2025.05.006_bib0006","article-title":"Multiple myeloma: an overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat Care Soc Pract"},{"key":"10.1016\/j.clml.2025.05.006_bib0007","article-title":"Real world evidence of epidemiological trends, clinical presentation, and prognostic outcomes of multiple myeloma (2007-2021)","volume":"11","author":"Elsabah","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.clml.2025.05.006_bib0008","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.05.006_bib0009","article-title":"First line treatment of newly diagnosed transplant eligible multiple myeloma recommendations from a Canadian consensus guideline consortium","author":"Khan","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.clml.2025.05.006_bib0010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.clml.2023.01.016","article-title":"First line treatment of newly diagnosed transplant ineligible multiple myeloma: recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium","volume":"23","author":"Cote","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.clml.2025.05.006_bib0011","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2022.01.011","article-title":"Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma","volume":"22","author":"Dimopoulos","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.05.006_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100808","article-title":"Improving outcomes for patients with relapsed multiple myeloma: challenges and considerations of current and emerging treatment options","volume":"49","author":"Ramasamy","year":"2021","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.clml.2025.05.006_bib0013","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.05.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113921","article-title":"Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: an analysis using linked Nordic registries","volume":"201","author":"Abildgaard","year":"2024","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.clml.2025.05.006_bib0015","first-page":"474","article-title":"Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) database","volume":"5","author":"Kaedbey","year":"2024","journal-title":"EJ Haem"},{"issue":"4","key":"10.1016\/j.clml.2025.05.006_bib0016","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/HS9.0000000000000045","article-title":"Long-term outcomes in patients with multiple myeloma: a retrospective analysis of the Dutch population-based haematological registry for observational studies (PHAROS)","volume":"2","author":"Verelst","year":"2018","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.clml.2025.05.006_bib0017","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/10428194.2022.2140284","article-title":"Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study","volume":"64","author":"Wang","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.clml.2025.05.006_bib0018","first-page":"917","article-title":"Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: a retrospective US claims database analysis","volume":"29","author":"Yang","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"10.1016\/j.clml.2025.05.006_bib0019","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/10428194.2020.1827253","article-title":"Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data","volume":"62","author":"Braunlin","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.clml.2025.05.006_bib0020","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.clml.2024.07.014","article-title":"Pomalidomide\/Daratumumab\/Dexamethasone in relapsed or refractory multiple myeloma: final overall survival from MM-014","volume":"24","author":"Bahlis","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"10.1016\/j.clml.2025.05.006_bib0021","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.05.006_bib0022","unstructured":"Alberta Netcare. Pharmaceutical information network (PIN). Accessed: December 05, 2024, https:\/\/www.albertanetcare.ca\/learningcentre\/pharmaceutical-information-network.htm"},{"key":"10.1016\/j.clml.2025.05.006_bib0023","unstructured":"Canadian Institute for Health Information. Discharge abstract database (DAD) metadata. Accessed: December 05, 2024, https:\/\/www.cihi.ca\/en\/discharge-abstract-database-dad-metadata"},{"key":"10.1016\/j.clml.2025.05.006_bib0024","unstructured":"Canadian Institute for Health Information. National Ambulatory Care Reporting System (NACRS) Metadata. Accessed: December 05, 2024, https:\/\/www.cihi.ca\/en\/national-ambulatory-care-reporting-system-nacrs-metadata"},{"key":"10.1016\/j.clml.2025.05.006_bib0025","unstructured":"Canadian Institute for Health Information. DAD Data elements, 2024-2025. Ottawa, ON: CIHI; 2024. Accessed: December 05, 2024. https:\/\/www.cihi.ca\/sites\/default\/files\/document\/dad-data-elements-2024-2025-en.pdf"},{"key":"10.1016\/j.clml.2025.05.006_bib0026","first-page":"218","article-title":"Exploring patient path through Sankey diagram: a proof of concept","volume":"270","author":"Lamer","year":"2020","journal-title":"Stud Health Technol Inform"},{"issue":"3","key":"10.1016\/j.clml.2025.05.006_bib0027","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(dagger)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"year":"2024","series-title":"CDA-AMC Reimbursement Review. Provisional Funding Algorithm","key":"10.1016\/j.clml.2025.05.006_bib0028"},{"issue":"1","key":"10.1016\/j.clml.2025.05.006_bib0029","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clml.2025.05.006_bib0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41408-023-00883-x","article-title":"Redefining attrition in multiple myeloma (MM): a canadian myeloma research group (CMRG) analysis","volume":"13","author":"McCurdy","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2025.05.006_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030962","article-title":"Attrition rates in multiple myeloma treatment under real world conditions-an analysis from the Austrian myeloma registry (AMR)","volume":"15","author":"Benda","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.clml.2025.05.006_bib0032","first-page":"5859","article-title":"Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed\/refractory multiple myeloma","volume":"30","author":"Nathwani","year":"2022","journal-title":"Support Care Cancer"},{"issue":"11","key":"10.1016\/j.clml.2025.05.006_bib0033","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1634\/theoncologist.2018-0724","article-title":"Patient-reported factors in treatment satisfaction in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"24","author":"Chari","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.clml.2025.05.006_bib0034","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ejh.12876","article-title":"Economic burden of relapsed or refractory multiple myeloma: results from an international trial","volume":"99","author":"Robinson","year":"2017","journal-title":"Eur J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:17:21Z","timestamp":1762600641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2152265025001582"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes for Multiple Myeloma Patients With Prior Exposure to a Combination of a Proteasome Inhibitor and an Immunomodulatory Agent in Alberta, Canada","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}